Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta ‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

ConclusionThis NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis.

Source: Thoracic Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Huang ‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang Tags: ORIGINAL ARTICLE Source Type: research